Literature DB >> 26811256

Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia.

Ming Teng Koh1, Yi Shao2, Andrew Sherwood2, Dani R Smith2.   

Abstract

The hippocampus of patients with schizophrenia displays aberrant excess neuronal activity which affects cognitive function. Animal models of the illness have recapitulated the overactivity in the hippocampus, with a corresponding regionally localized reduction of inhibitory interneurons, consistent with that observed in patients. To better understand whether cognitive function is similarly affected in these models of hippocampal overactivity, we tested a ketamine mouse model of schizophrenia for cognitive performance in hippocampal- and medial prefrontal cortex (mPFC)-dependent tasks. We found that adult mice exposed to ketamine during adolescence were impaired on a trace fear conditioning protocol that relies on the integrity of the hippocampus. Conversely, the performance of the mice was normal on a delayed response task that is sensitive to mPFC damage. We confirmed that ketamine-exposed mice had reduced parvalbumin-positive interneurons in the hippocampus, specifically in the CA1, but not in the mPFC in keeping with the behavioral findings. These results strengthened the utility of the ketamine model for preclinical investigations of hippocampal overactivity in schizophrenia.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Delayed response task; Fear conditioning; Hippocampus; Medial prefrontal cortex; Overactivity

Mesh:

Substances:

Year:  2016        PMID: 26811256      PMCID: PMC4762714          DOI: 10.1016/j.schres.2016.01.023

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  63 in total

1.  Time-dependent relationship between the dorsal hippocampus and the prefrontal cortex in spatial memory.

Authors:  Inah Lee; Raymond P Kesner
Journal:  J Neurosci       Date:  2003-02-15       Impact factor: 6.167

Review 2.  Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia.

Authors:  Paul A Dudchenko; John Talpos; Jared Young; Mark G Baxter
Journal:  Neurosci Biobehav Rev       Date:  2012-03-22       Impact factor: 8.989

3.  Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.

Authors:  Germana Silva Vasconcelos; Naiara Coelho Ximenes; Caren Nádia Soares de Sousa; Tatiana de Queiroz Oliveira; Laio Ladislau Lopes Lima; David Freitas de Lucena; Clarissa Severino Gama; Danielle Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Schizophr Res       Date:  2015-04-30       Impact factor: 4.939

4.  Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning.

Authors:  Jonathan L Brigman; Tara Wright; Giuseppe Talani; Shweta Prasad-Mulcare; Seiichiro Jinde; Gail K Seabold; Poonam Mathur; Margaret I Davis; Roland Bock; Richard M Gustin; Roger J Colbran; Veronica A Alvarez; Kazu Nakazawa; Eric Delpire; David M Lovinger; Andrew Holmes
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

5.  Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model.

Authors:  Kathryn M Gill; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2014-04-30       Impact factor: 5.176

6.  Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons.

Authors:  S B Floresco; C L Todd; A A Grace
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

Review 7.  To model a psychiatric disorder in animals: schizophrenia as a reality test.

Authors:  B K Lipska; D R Weinberger
Journal:  Neuropsychopharmacology       Date:  2000-09       Impact factor: 7.853

8.  Selective lesioning of the cholinergic septo-hippocampal pathway does not disrupt spatial short-term memory: a comparison with the effects of fimbria-fornix lesions.

Authors:  Boyer D Winters; Stephen B Dunnett
Journal:  Behav Neurosci       Date:  2004-06       Impact factor: 1.912

9.  A role for prefrontal cortex in memory storage for trace fear conditioning.

Authors:  Jason D Runyan; Anthony N Moore; Pramod K Dash
Journal:  J Neurosci       Date:  2004-02-11       Impact factor: 6.167

10.  Disruptions in spatial working memory, but not short-term memory, induced by repeated ketamine exposure.

Authors:  Takeshi Enomoto; Stan B Floresco
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-03-21       Impact factor: 5.067

View more
  10 in total

1.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

2.  Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Aya-Ebi Okubo Eneni; Abayomi Mayowa Ajayi; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Neurochem Res       Date:  2018-06-28       Impact factor: 3.996

3.  A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.

Authors:  Ming Teng Koh; Paige S Ahrens; Michela Gallagher
Journal:  Behav Neurosci       Date:  2018-04       Impact factor: 1.912

Review 4.  Parvalbumin interneuron vulnerability and brain disorders.

Authors:  Jacob B Ruden; Laura L Dugan; Christine Konradi
Journal:  Neuropsychopharmacology       Date:  2020-07-28       Impact factor: 7.853

Review 5.  Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia.

Authors:  D A Maas; A Vallès; G J M Martens
Journal:  Transl Psychiatry       Date:  2017-07-18       Impact factor: 6.222

6.  Glutamate Deregulation in Ketamine-Induced Psychosis-A Potential Role of PSD95, NMDA Receptor and PMCA Interaction.

Authors:  Malwina Lisek; Bozena Ferenc; Maciej Studzian; Lukasz Pulaski; Feng Guo; Ludmila Zylinska; Tomasz Boczek
Journal:  Front Cell Neurosci       Date:  2017-06-28       Impact factor: 5.505

7.  Developmental dysfunction of prefrontal-hippocampal networks in mouse models of mental illness.

Authors:  Victoria C Oberlander; Xiaxia Xu; Mattia Chini; Ileana L Hanganu-Opatz
Journal:  Eur J Neurosci       Date:  2019-06-11       Impact factor: 3.386

8.  (R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency.

Authors:  Lace M Riggs; Xiaoxian An; Edna F R Pereira; Todd D Gould
Journal:  Transl Psychiatry       Date:  2021-11-12       Impact factor: 6.222

9.  Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review.

Authors:  Jurriaan F M Strous; Cees J Weeland; Femke A van der Draai; Joost G Daams; Damiaan Denys; Anja Lok; Robert A Schoevers; Martijn Figee
Journal:  Front Neuroanat       Date:  2022-03-18       Impact factor: 3.856

10.  Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling.

Authors:  Yayan Luo; Yang Yu; Minling Zhang; Hongbo He; Ni Fan
Journal:  Mol Psychiatry       Date:  2020-06-02       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.